Ben Around

FDA Calendar Updates: AspenBio, CytRx, Cephalon, Pozen, Sanofi, AMAG

CYTR has the potential to fly, because there is little notice of the secondary use of arimoclomol in treating stroke victims up to 48 hours after the initial stroke.

The stroke treatment possibilities and the 45% stake in RXII are the reason I am very long on this stock.

Do your own DD.

"Arimoclomol is an orally administered molecular chaperone regulator drug candidate that is being considered as a treatment for ALS and stroke recovery. Molecular chaperone regulator drugs are believed to function by regulating a normal cellular protein repair pathway through the activation or inhibition of “molecular chaperones.” Molecular chaperones detect proteins that are misfolded, and have the ability to refold those proteins into the appropriate, non-toxic shape.

In February 2009, CytRx announced the commencement of a Phase 2/3 adaptive clinical trial, sponsored by the ALS Association and the FDA’s Office of Orphan Products Development OOPD, to study arimoclomol in a subset of patients with the inherited or familial form of ALS. In March 2009, the Company reported that arimoclomol had demonstrated statistically significant neurorestorative results in a preclinical embolic stroke trial. This data supported previous preclinical results indicating improvement in stroke recovery following oral arimoclomol administration up to 48 hours post-stroke."

See the article @
finance.yahoo.com/news...

Watch for More Coming Biotech Acquisitions

The writer failed to mention Elan. The recent bad news has pounded the PPS to a rediculous $10 that makes them a easy target for a tokeover. I would bet, I am buying at this level, that we will see a bid from BIIB to get Elan on the cheap.

Ichan wants to get BIIB to sell themselves but if they owned all of Elan they would be a much stronger company.

Immunogen and Seattle Genetics: Verging on an Inflection Point

Very interesting article.
I have been in and out of imgn for years and watch it track from 3-6, usually with some justification of the price variations from external influences.
This latest drop on tuesday (June 3) completely baffles me. I look at it as a buy in again opportunity since I can't see any other reason other than small investor interest.

Any in comments on Tuesday's action?